-$0.32 EPS Expected for Phio Pharmaceuticals Corp. (NASDAQ:PHIO) This Quarter

Wall Street analysts expect that Phio Pharmaceuticals Corp. (NASDAQ:PHIO) will post earnings of ($0.32) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Phio Pharmaceuticals’ earnings. Phio Pharmaceuticals reported earnings per share of ($0.41) during the same quarter last year, which would indicate a positive year-over-year growth rate of 22%. The business is expected to issue its next quarterly earnings results on Thursday, March 24th.

According to Zacks, analysts expect that Phio Pharmaceuticals will report full year earnings of ($1.11) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the business will report earnings of $0.98 per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Phio Pharmaceuticals.

Phio Pharmaceuticals (NASDAQ:PHIO) last posted its earnings results on Wednesday, November 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.03).

A number of equities research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Phio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, November 17th. HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Phio Pharmaceuticals in a report on Monday, November 15th.

Hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its position in shares of Phio Pharmaceuticals by 38.3% during the first quarter. Dimensional Fund Advisors LP now owns 34,808 shares of the company’s stock worth $93,000 after acquiring an additional 9,631 shares during the last quarter. Virtu Financial LLC grew its position in shares of Phio Pharmaceuticals by 74.7% during the second quarter. Virtu Financial LLC now owns 27,110 shares of the company’s stock worth $61,000 after acquiring an additional 11,588 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of Phio Pharmaceuticals during the second quarter worth approximately $43,000. Geode Capital Management LLC grew its position in shares of Phio Pharmaceuticals by 22.5% during the third quarter. Geode Capital Management LLC now owns 107,192 shares of the company’s stock worth $216,000 after acquiring an additional 19,691 shares during the last quarter. Finally, Cetera Investment Advisers purchased a new position in shares of Phio Pharmaceuticals during the third quarter worth approximately $61,000. 5.19% of the stock is currently owned by institutional investors.

Shares of NASDAQ PHIO traded down $0.02 during mid-day trading on Thursday, reaching $1.42. The company’s stock had a trading volume of 80,283 shares, compared to its average volume of 760,139. The stock has a 50-day moving average of $1.75 and a two-hundred day moving average of $1.92. The stock has a market capitalization of $19.22 million, a P/E ratio of -1.17 and a beta of 1.96. Phio Pharmaceuticals has a 1-year low of $1.32 and a 1-year high of $4.36.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Recommended Story: Dividend Kings

Get a free copy of the Zacks research report on Phio Pharmaceuticals (PHIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.